Abstract
Tumor-reactive T cell exhaustion prevents the success of immune therapies. Pegilodecakin activates intratumoral CD8+ T cells in mice and induces objective tumor responses in patients. Here we report that pegilodecakin induces hallmarks of CD8+ T cell immunity in cancer patients, including elevation of interferon-γ and GranzymeB, expansion and activation of intratumoral CD8+ T cells, and proliferation and expansion of LAG-3+ PD-1+ CD8+ T cells. On pegilodecakin, newly expanded T cell clones, undetectable at baseline, become 1%–10% of the total T cell repertoire in the blood. Elevation of interleukin-18, expansion of LAG-3+ PD-1+ T cells and novel T cell clones each correlated with objective tumor responses. Combined pegilodecakin with anti-PD-1 increased the expansion of LAG-3+ PD-1+ CD8+ T cells. Naing et al. report that pegilodecakin, PEGylated IL-10, which achieves objective tumor responses in patients, induces hallmarks of CD8+ T cell immunity in cancer patients. Pegilodecakin promotes expansion of underrepresented T cell clones as well as LAG-3+ PD-1+ CD8+ T cells, which are further induced by anti-PD-1.
Original language | English (US) |
---|---|
Pages (from-to) | 775-791.e3 |
Journal | Cancer cell |
Volume | 34 |
Issue number | 5 |
DOIs | |
State | Published - Nov 12 2018 |
Keywords
- AM0010
- CD8 T cell
- IL-10
- PEGylated Interleukin 10
- T cell invigoration
- Th1
- clinical trial
- clonal expansion
- clonality
- pegilodecakin
ASJC Scopus subject areas
- Oncology
- Cell Biology
- Cancer Research